Avinger

Lumivascular (Avinger) is a private medical device innovator focused on transforming the treatment of coronary Chronic Total Occlusions (CTOs). Its core technology platform integrates real-time intravascular OCT imaging directly into a CTO-crossing catheter, aiming to provide unprecedented procedural accuracy while reducing reliance on fluoroscopy and contrast dye. Founded by seasoned medtech veterans, the company holds an extensive IP portfolio and is developing a platform intended to expand global access to complex CTO procedures. It appears to be in the late-stage development or early commercial phase, building on the founders' prior successful exits in the vascular device space.

Integrated real-time intravascular Optical Coherence Tomography (OCT) imaging combined with a Chronic Total Occlusion (CTO) crossing catheter.

Competition includes large medtech players (e.g., Abbott, Boston Scientific, Medtronic) offering advanced guidewires, microcatheters, and intravascular ultrasound (IVUS) for CTO crossing. Lumivascular's differentiation is the direct integration of high-resolution OCT imaging into the therapeutic catheter, a unique approach not currently available commercially for coronary CTOs.